This is the authors' abstract. We don't add key points for this paper.
The complexes ( N,N ‘-tmeda)Zn(ESiMe 3 ) 2 (E = S, 1a; E = Se, 2a; E = Te, 3a ) and (3,5-Me 2 -C 5 H 3 N) 2 Zn(ESiMe 3 ) 2 (E = S, 1b; E = Se, 2b; E = Te, 3b ) have been prepared in high yield by the reaction of E(SiMe 3 ) 2 with ( N,N ‘-tmeda)Zn(OAc) 2 ( 4a ) and (3,5-Me 2 -C 5 H 3 N) 2 Zn(OAc) 2 ( 4b ), respectively. Complexes 1 − 3 have been characterized spectroscopically and by means of single-crystal X-ray diffraction. All six complexes exist in the solid state as monomeric species with terminally bonded trimethylsilylchalcogenolate moieties and a distorted tetrahedral geometry of the zinc center.
No takes yet. Share an insight, caveat, or question.
DeGroot et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: